Colon CancerNCT04780477
Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer
A study testing High Fiber Diet Featuring Legumes (HLD) and Healthy American Diet in people with Colon Cancer and Obesity, run by Emory University at 1 site in United States.
Trial summary
This study tests whether a high-fiber diet based on legumes, such as dry beans, can lead to sustained reductions in obesity and colon cancer risk in persons at highest risk, namely overweight or obese, post-polypectomy patients. Read more about this study
- Who is it for?
- Ages 40 to 75 years
- Conditions the study is for
- Colon Cancer, Obesity
- What is being tested?
- High Fiber Diet Featuring Legumes (HLD) and Healthy American Diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Jun 2021to 30 Jun 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- free-living adults 40 to 75 years old
- BMI 25-40 kg/m^2
- able to provide documentation confirming a colonoscopy within 3 years that found ≥1 adenoma >0.5 cm or a sessile serrated polyp (any)
- English speaking
- ambulatory, able to pick up food, participate in clinical exams and laboratory tests
- able to provide informed consent
Who cannot join
- serious and/or unstable medical condition as deemed by study physician
- history of colorectal cancer, bowel resection, polyposis syndrome, or inflammatory bowel disease
- smoked regularly in the past year
- dietary restrictions substantially limiting compliance (e.g., must be willing to be randomized to either diet)
- planning on substantially changing usual exercise behavior in the next 6 months
- regular or recent use of prescription medication that may alter inflammation markers or gut function as deemed by study physician
- pregnant women, breast feeding women, or women planning pregnancy within the year of active study participation
Trial locations and contacts
1 site in 1 country.
United States1 site
Rollins School of Public Health, Emory University
Atlanta, Georgia, 30322
About this study
This study tests whether a high-fiber diet based on legumes, such as dry beans, can lead to sustained reductions in obesity and colon cancer risk in persons at highest risk, namely overweight or obese, post-polypectomy patients.
Read the detailed description
An important knowledge gap concerns the role of fiber in sustaining reduced energy intake to simultaneously manage weight and influence human colorectal cancer risk. Epidemiologic studies have shown an association between a high fiber diet featuring legumes (HLD) and reduced obesity and lower risk for adenoma recurrence or colorectal cancer. There are many plausible mechanisms to explain why high-fiber diets, and especially a HLD, may reduce colorectal cancer risk. First, fiber is fermented by the colonic microbiota to produce short chain fatty acids (SCFA). The SCFA, butyrate, has a remarkable array of colonic mucosal health promoting, anti-inflammatory, and anti-neoplastic properties. Secondly, microbiota break down plant cell walls releasing phytochemicals, which also have powerful anti-inflammatory and anti-carcinogenic effects. Thirdly, colonic transit is accelerated, reducing contact time with luminal carcinogens, such as heterocyclic amines formed from cooked red meat, and secondary bile acids, induced by a high fat diet and synthesized by the colonic microbiota.
Dr. Stephen O'Keefe's lab performed a human randomized controlled crossover feeding study (participants receive both diets) comparing high and low- fiber diets. The study measured mucosal biomarkers of cancer risk (proliferation - % epithelial cells staining positive for Ki67, inflammation - cluster of differentiation 3 (CD3)+ intraepithelial lymphocytes, cluster of differentiation 68 (CD68)+ lamina propria macrophages) made by fecal sampling and colonoscopy. Results suggested that within weeks these markers responded favorably to the high-fiber diet with proliferative rates and inflammatory biomarkers decreasing and microbiota composition adapting to increase butyrogenesis.
The researchers of this study have previously found that fiber may also reduce cancer risk indirectly by promoting weight loss, improving insulin sensitivity and decreasing inflammation. On average, individuals consume a similar weight of food daily; thus, replacing energy dense foods (higher kcal/g, e.g., high fat) with lower energy density foods (lower kcal/g), like legumes, should potentiate weight control. Viscous fiber intake is associated with longer gastric emptying times which over time might contribute to postponing the next eating occasion. Diet may also induce changes in gut microbiome composition leading to negative energy balance. Emerging human evidence links the gut microbiome with insulin resistance, inflammation, and obesity and with adenomatous polyps and colon cancer. In this current study, characterizing gut motility, microbiome, and metabolome composition profiles that may influence weight loss and have a role in the prevention or recurrence of adenomas and colorectal cancer, will provide novel and potentially therapeutic information.
The goal of the research is to conduct a clinical trial featuring study-provided pre-portioned entrées and strategic nutritional instruction to guide participants to integrate legumes into a healthy high-fiber diet pattern. Participants will be provided two entrées per day during months 1 through 3, and one entrée per day during months 4 through 6. Participants will continue their diets during months 7 through 12 but will be responsible for food preparation. The research will target a population at high risk for colorectal cancer, overweight and obese participants with a history of a colon polyp in the past 3 years, to test whether a high-legume, high-fiber diet will simultaneously increase weight loss and suppress intestinal biomarkers of cancer risk compared to a control diet (healthy American). In addition, it will explore potential mechanisms through which the high-legume intervention diet facilitates weight loss and intestinal health.
- Conditions
- Colon Cancer, Obesity
- Being tested
- High Fiber Diet Featuring Legumes (HLD), Healthy American Diet
- Keywords
- Fiber-rich Foods, Legumes, Weight loss, Intestinal health, Cancer prevention
- Medical subject headings
- Colonic Neoplasms, Obesity, Weight Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High Fiber Diet Featuring Legumes (HLD)Dietary supplement
The high fiber diet featuring legumes (HLD) provides pre-portioned entrées for two meals per day in months 1-3, and one meal per day in months 4-6. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250 grams (g) of legumes per day (~1 ½ cups cooked legumes) in months 1-3 provided in two pre-portioned single serving entrées (i.e. ~125g in each serving). A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
Healthy American DietDietary supplement
The healthy American diet provides pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week.
| Study group | Role | What they receive |
|---|---|---|
| High Fiber Diet Featuring Legumes (HLD) | Experimental | Participants randomized to the high fiber diet featuring legumes (HLD) will add approximately 30 grams of dietary fiber per day from legume dishes, ensuring a total intake of approximately 50 grams of dietary fiber per day. Receives: Dietary Supplement: High Fiber Diet Featuring Legumes (HLD) |
| Healthy American Diet Control Arm | Active comparator | Participants randomized to the healthy American diet control arm will receive pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat. Receives: Dietary Supplement: Healthy American Diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Body Weight
Body weight is measured (in pounds) on a regularly calibrated digital scale while wearing light clothing without shoes.
Measured: Baseline, Month 6 (end of intense intervention)
Change in Ki-67+ Level
Mucosal biopsies are obtained to measure the colonic mucosal proliferative biomarker Ki-67+.
Measured: Baseline, Month 6 (end of intense intervention)
Secondary outcomes (8)
Change in Body Weight During Maintenance Period
Body weight is measured (in pounds) on a regularly calibrated digital scale while wearing light clothing without shoes.
Measured: Month 6, Month 12
Change in Ki-67+ Level During Maintenance Period
Mucosal biopsies are obtained to measure the colonic mucosal proliferative biomarker Ki-67+.
Measured: Month 6, Month 12
Change in Gut Transit Time
Gut transit time is assessed using an indigestible single-use SmartPill capsule, a receiver, and display software. The SmartPill capsules were discontinued and no longer available after 2023 so participants beginning after January 19, 2024 will not complete this assessment.
Measured: Baseline, Month 6 (end of intense intervention)
Change in Fasting Plasma Insulin Level
Fasting plasma insulin, a biomarker of insulin resistance, is measured by blood test.
Measured: Baseline, Month 6, Month 12
Change in Fasting Plasma Glucose Level
Fasting plasma glucose, a biomarker of insulin resistance, is measured by blood test.
Measured: Baseline, Month 6, Month 12
Change in Serum C-reactive Protein
Serum C-reactive protein, an indicator of systemic inflammation, is measured by blood test.
Measured: Baseline, Month 6, Month 12
Change in CD3+ Intraepithelial Lymphocytes Count
CD3+ intraepithelial lymphocytes, a colonic mucosal inflammatory biomarker of colon cancer risk, is measured by mucosal biopsy.
Measured: Baseline, Month 6, Month 12
Change in CD68+ Lamina Propia Macrophages Count
CD68+ lamina propia macrophages, a colonic mucosal inflammatory biomarker of colon cancer risk, is measured by mucosal biopsy.
Measured: Baseline, Month 6, Month 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2021
- Study start29 Jun 2021
- Primary completion29 May 2025
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Colon CancerStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Principal investigator, Terry Hartman, Emory University
- Investigators
- Terry Hartman, PhD, MPH, RD, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04780477
- Sponsor's protocol ID
- STUDY00000563
- Other IDs
- R01CA245063
- Status last verified
- Aug 2026
- First submitted
- 2 Mar 2021
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified participant phenotypic data will be made available for sharing but limited to health/biomedical purposes including age, obesity status, presence of colon polyps and history of diabetes. The data will be coded and only the coded data set, and not the master list, will be shared.
Publications
Hartman TJ, Christie J, Wilson A, Ziegler TR, Methe B, Flanders WD, Rolls BJ, Loye Eberhart B, Li JV, Huneault H, Cousineau B, Perez MR, O'Keefe SJD. Fibre-rich Foods to Treat Obesity and Prevent Colon Cancer trial study protocol: a randomised clinical trial of fibre-rich legumes targeting the gut microbiome, metabolome and gut transit time of overweight and obese patients with a history of noncancerous adenomatous polyps. BMJ Open. 2024 Feb 5;14(2):e081379. doi: 10.1136/bmjopen-2023-081379.
PubMed 38316601
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer
- ClinicalTrials.gov ID
- NCT04780477
- Acronym / sponsor ID
- STUDY00000563
- Conditions
- Colon Cancer, Obesity
- Keywords
- Fiber-rich Foods, Legumes, Weight loss, Intestinal health, Cancer prevention
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 29 Jun 2021 (actual)
- Primary completion
- 29 May 2025 (actual)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 3 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study tests whether a high-fiber diet based on legumes, such as dry beans, can lead to sustained reductions in obesity and colon cancer risk in persons at highest risk, namely overweight or obese, post-polypectomy patients.
Detailed description
An important knowledge gap concerns the role of fiber in sustaining reduced energy intake to simultaneously manage weight and influence human colorectal cancer risk. Epidemiologic studies have shown an association between a high fiber diet featuring legumes (HLD) and reduced obesity and lower risk for adenoma recurrence or colorectal cancer. There are many plausible mechanisms to explain why high-fiber diets, and especially a HLD, may reduce colorectal cancer risk. First, fiber is fermented by the colonic microbiota to produce short chain fatty acids (SCFA). The SCFA, butyrate, has a remarkable array of colonic mucosal health promoting, anti-inflammatory, and anti-neoplastic properties. Secondly, microbiota break down plant cell walls releasing phytochemicals, which also have powerful anti-inflammatory and anti-carcinogenic effects. Thirdly, colonic transit is accelerated, reducing contact time with luminal carcinogens, such as heterocyclic amines formed from cooked red meat, and secondary bile acids, induced by a high fat diet and synthesized by the colonic microbiota.
Dr. Stephen O'Keefe's lab performed a human randomized controlled crossover feeding study (participants receive both diets) comparing high and low- fiber diets. The study measured mucosal biomarkers of cancer risk (proliferation - % epithelial cells staining positive for Ki67, inflammation - cluster of differentiation 3 (CD3)+ intraepithelial lymphocytes, cluster of differentiation 68 (CD68)+ lamina propria macrophages) made by fecal sampling and colonoscopy. Results suggested that within weeks these markers responded favorably to the high-fiber diet with proliferative rates and inflammatory biomarkers decreasing and microbiota composition adapting to increase butyrogenesis.
The researchers of this study have previously found that fiber may also reduce cancer risk indirectly by promoting weight loss, improving insulin sensitivity and decreasing inflammation. On average, individuals consume a similar weight of food daily; thus, replacing energy dense foods (higher kcal/g, e.g., high fat) with lower energy density foods (lower kcal/g), like legumes, should potentiate weight control. Viscous fiber intake is associated with longer gastric emptying times which over time might contribute to postponing the next eating occasion. Diet may also induce changes in gut microbiome composition leading to negative energy balance. Emerging human evidence links the gut microbiome with insulin resistance, inflammation, and obesity and with adenomatous polyps and colon cancer. In this current study, characterizing gut motility, microbiome, and metabolome composition profiles that may influence weight loss and have a role in the prevention or recurrence of adenomas and colorectal cancer, will provide novel and potentially therapeutic information.
The goal of the research is to conduct a clinical trial featuring study-provided pre-portioned entrées and strategic nutritional instruction to guide participants to integrate legumes into a healthy high-fiber diet pattern. Participants will be provided two entrées per day during months 1 through 3, and one entrée per day during months 4 through 6. Participants will continue their diets during months 7 through 12 but will be responsible for food preparation. The research will target a population at high risk for colorectal cancer, overweight and obese participants with a history of a colon polyp in the past 3 years, to test whether a high-legume, high-fiber diet will simultaneously increase weight loss and suppress intestinal biomarkers of cancer risk compared to a control diet (healthy American). In addition, it will explore potential mechanisms through which the high-legume intervention diet facilitates weight loss and intestinal health.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| High Fiber Diet Featuring Legumes (HLD) | Experimental | Dietary Supplement: High Fiber Diet Featuring Legumes (HLD)Participants randomized to the high fiber diet featuring legumes (HLD) will add approximately 30 grams of dietary fiber per day from legume dishes, ensuring a total intake of approximately 50 grams of dietary fiber per day. |
| Healthy American Diet Control Arm | Active comparator | Dietary Supplement: Healthy American DietParticipants randomized to the healthy American diet control arm will receive pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat. |
Who may qualify
- Ages
- 40 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- free-living adults 40 to 75 years old
- BMI 25-40 kg/m^2
- able to provide documentation confirming a colonoscopy within 3 years that found ≥1 adenoma >0.5 cm or a sessile serrated polyp (any)
- English speaking
- ambulatory, able to pick up food, participate in clinical exams and laboratory tests
Key exclusion criteria (7 listed)
- serious and/or unstable medical condition as deemed by study physician
- history of colorectal cancer, bowel resection, polyposis syndrome, or inflammatory bowel disease
- smoked regularly in the past year
- dietary restrictions substantially limiting compliance (e.g., must be willing to be randomized to either diet)
- planning on substantially changing usual exercise behavior in the next 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High Fiber Diet Featuring Legumes (HLD)The high fiber diet featuring legumes (HLD) provides pre-portioned entrées for two meals per day in months 1-3, and one meal per day in months 4-6. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. The HLD will contain approximately 250 grams (g) of legumes per day (~1 ½ cups cooked legumes) in months 1-3 provided in two pre-portioned single serving entrées (i.e. ~125g in each serving). A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week. | Dietary supplement | High Fiber Diet Featuring Legumes (HLD) |
| Healthy American DietThe healthy American diet provides pre-portioned meal replacement entrées with legumes replaced by lean chicken or meat. Participants continue on the diet in months 7-12 but assume responsibility for food preparation. A study nutritionist provides in-person and written guidance for including side dishes that are nutritionally balanced with energy intake to lose 1-2 pounds of weight per week. | Dietary supplement | Healthy American Diet Control Arm |
Primary outcome
Change in Body Weight
Time frame: Baseline, Month 6 (end of intense intervention)
Body weight is measured (in pounds) on a regularly calibrated digital scale while wearing light clothing without shoes.
Change in Ki-67+ Level
Time frame: Baseline, Month 6 (end of intense intervention)
Mucosal biopsies are obtained to measure the colonic mucosal proliferative biomarker Ki-67+.
8 secondary outcomes
Change in Body Weight During Maintenance Period
Time frame: Month 6, Month 12
Change in Ki-67+ Level During Maintenance Period
Time frame: Month 6, Month 12
Change in Gut Transit Time
Time frame: Baseline, Month 6 (end of intense intervention)
Change in Fasting Plasma Insulin Level
Time frame: Baseline, Month 6, Month 12
Change in Fasting Plasma Glucose Level
Time frame: Baseline, Month 6, Month 12
Change in Serum C-reactive Protein
Time frame: Baseline, Month 6, Month 12
Change in CD3+ Intraepithelial Lymphocytes Count
Time frame: Baseline, Month 6, Month 12
Change in CD68+ Lamina Propia Macrophages Count
Time frame: Baseline, Month 6, Month 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
- Derived from this study: PubMed 38316601Hartman TJ, Christie J, Wilson A, Ziegler TR, Methe B, Flanders WD, Rolls BJ, Loye Eberhart B, Li JV, Huneault H, Cousineau B, Perez MR, O'Keefe SJD. Fibre-rich Foods to Treat Obesity and Prevent Colon Cancer trial study protocol: a randomised clinical trial of fibre-rich legumes targeting the gut microbiome, metabolome and gut transit time of overweight and obese patients with a history of noncancerous adenomatous polyps. BMJ Open. 2024 Feb 5;14(2):e081379. doi: 10.1136/bmjopen-2023-081379.
- Individual participant dataSharing planned: Yes. De-identified participant phenotypic data will be made available for sharing but limited to health/biomedical purposes including age, obesity status, presence of colon polyps and history of diabetes. The data will be coded and only the coded data set, and not the master list, will be shared.
Related trials for Colon Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Not yet recruitingPhase 2
Alberta Cancer Exercise Dose in Colorectal Cancer
Cancer, Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Terry Hartman, PhD, MPH, RD principal investigator
Emory University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High Fiber Diet Featuring Legumes (HLD) and Healthy American Diet in people with Colon Cancer and Obesity, run by Emory University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Body Weight (time frame: Baseline, Month 6 (end of intense intervention)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04780477, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.